Moderna Inc. (MRNA)
Moderna: Ready For The Redemption Arc
Moderna's stock has faced heavy pressure from negative headlines, regulatory setbacks, and political uncertainty, but recent FDA approvals have stabilized sentiment. The company now boasts three approved respiratory vaccines, a strong cash position, and a robust pipeline, supporting a potential long-term growth narrative beyond COVID. Key risks remain: political headwinds, commercial execution, clinical trial outcomes, and high cash burn could impact future performance and investor confidence.
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
This Former Meme Stock, Down 93%, is a High-Upside Buy Right Now
Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago.
Moderna Stock Gains on Encouraging Flu Vaccine Data
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Executive Vice President of Research Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Huidong Wang My name is Gena Wang. I'm SMID Cap biotech analyst at the Barclays.
Here's Why Moderna (MRNA) Fell More Than Broader Market
Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. Good morning, everyone.
